Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets.
Biliary cancer
extrahepatic cholangiocarcinoma (EHCC)
gallbladder carcinoma (GBC)
intrahepatic cholangiocarcinoma (IHCC)
Journal
Journal of gastrointestinal oncology
ISSN: 2078-6891
Titre abrégé: J Gastrointest Oncol
Pays: China
ID NLM: 101557751
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
entrez:
9
8
2019
pubmed:
9
8
2019
medline:
9
8
2019
Statut:
ppublish
Résumé
Biliary tract cancers (BTCs) are a heterogeneous group of aggressive, rare malignancies with limited standard chemotherapeutic options for advanced disease. Recent studies have demonstrated potential novel biliary cancer targets and a possible role for immunotherapy in the treatment of patients with this disease. Intrahepatic cholangiocarcinoma (IHCC), extrahepatic cholangiocarcinoma (EHCC), and gallbladder carcinoma (GBC) are frequently grouped together in clinical trials despite differences in tumor biology. To further investigate tumor biology differences, we profiled 1,502 BTCs using next-generation sequencing (NGS), immunohistochemistry, IHCCs had higher rates of These findings support clinical molecular profiling of BTCs to inform potential therapeutic selection and clinical trial design based on the primary tumor's site of origin within the biliary tree.
Sections du résumé
BACKGROUND
BACKGROUND
Biliary tract cancers (BTCs) are a heterogeneous group of aggressive, rare malignancies with limited standard chemotherapeutic options for advanced disease. Recent studies have demonstrated potential novel biliary cancer targets and a possible role for immunotherapy in the treatment of patients with this disease. Intrahepatic cholangiocarcinoma (IHCC), extrahepatic cholangiocarcinoma (EHCC), and gallbladder carcinoma (GBC) are frequently grouped together in clinical trials despite differences in tumor biology.
METHODS
METHODS
To further investigate tumor biology differences, we profiled 1,502 BTCs using next-generation sequencing (NGS), immunohistochemistry,
RESULTS
RESULTS
IHCCs had higher rates of
CONCLUSIONS
CONCLUSIONS
These findings support clinical molecular profiling of BTCs to inform potential therapeutic selection and clinical trial design based on the primary tumor's site of origin within the biliary tree.
Identifiants
pubmed: 31392046
doi: 10.21037/jgo.2018.08.18
pii: jgo-10-04-652
pmc: PMC6657312
doi:
Types de publication
Journal Article
Langues
eng
Pagination
652-662Déclaration de conflit d'intérêts
Conflicts of Interest: Drs. Xiu and Poorman are employed by Caris Life Sciences. The other authors have no conflicts of interest to declare.
Références
Semin Liver Dis. 2004 May;24(2):189-99
pubmed: 15192791
Histol Histopathol. 2005 Jul;20(3):871-8
pubmed: 15944938
Cancer. 2006 Jan 15;106(2):361-5
pubmed: 16342166
Jpn J Clin Oncol. 2006 Sep;36(9):552-6
pubmed: 16887837
Am J Clin Oncol. 2009 Aug;32(4):348-52
pubmed: 19363436
N Engl J Med. 2010 Apr 8;362(14):1273-81
pubmed: 20375404
Expert Rev Gastroenterol Hepatol. 2010 Aug;4(4):395-7
pubmed: 20678012
Cancer Chemother Pharmacol. 2011 Sep;68(3):743-51
pubmed: 21170649
Lung Cancer. 2011 Oct;74(1):132-8
pubmed: 21367480
Br J Cancer. 2011 Jun 28;105(1):131-8
pubmed: 21673683
J Clin Oncol. 2012 Jun 1;30(16):1934-40
pubmed: 22529261
World J Gastrointest Oncol. 2012 May 15;4(5):94-102
pubmed: 22645632
Oncology. 2012;83(2):57-66
pubmed: 22760079
J Clin Oncol. 2012 Sep 20;30(27):e271-3
pubmed: 22851567
J Clin Oncol. 2012 Sep 10;30(26):3287-96
pubmed: 22869872
Br J Cancer. 2013 Apr 2;108(6):1238-44
pubmed: 23481186
Nat Genet. 2013 Dec;45(12):1470-1473
pubmed: 24185509
Onco Targets Ther. 2013 Oct 30;6:1545-52
pubmed: 24204165
Ann Oncol. 2014 Dec;25(12):2328-38
pubmed: 24769639
J Clin Oncol. 2015 Jan 20;33(3):244-50
pubmed: 25366685
Cancer Epidemiol Biomarkers Prev. 2014 Dec;23(12):2965-70
pubmed: 25392179
Ann Oncol. 2015 Apr;26(4):804-11
pubmed: 25573533
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
J Pharmacol Sci. 2015 Mar;127(3):319-25
pubmed: 25837929
J Clin Oncol. 2015 Aug 20;33(24):2617-22
pubmed: 25964250
J Hematol Oncol. 2015 May 29;8:58
pubmed: 26022204
Nat Genet. 2015 Sep;47(9):1003-10
pubmed: 26258846
BMC Cancer. 2015 Sep 03;15:615
pubmed: 26337466
Mol Carcinog. 2016 Dec;55(12):2037-2050
pubmed: 26757360
Nucleic Acids Res. 2016 Apr 7;44(6):2859-72
pubmed: 26837576
Science. 2016 Mar 25;351(6280):1463-9
pubmed: 26940869
J Clin Oncol. 2016 Jun 20;34(18):2141-7
pubmed: 27022117
Onco Targets Ther. 2016 Mar 09;9:1339-50
pubmed: 27022289
Cancer Res. 2016 Jul 1;76(13):3767-72
pubmed: 27197178
Transl Oncol. 2016 Jun;9(3):173-8
pubmed: 27267833
Cancer Immunol Res. 2016 Nov;4(11):959-967
pubmed: 27671167
J Gastrointest Oncol. 2016 Oct;7(5):797-803
pubmed: 27747093
Oncotarget. 2017 Jun 6;8(23):37923-37934
pubmed: 27888622
Cancer Discov. 2017 Jun;7(6):620-629
pubmed: 28242752
Clin Cancer Res. 2017 Aug 1;23(15):4066-4076
pubmed: 28356425
J Cancer. 2017 May 12;8(8):1395-1399
pubmed: 28638453
Cancer Discov. 2017 Oct;7(10):1116-1135
pubmed: 28667006
Mol Cancer Ther. 2017 Nov;16(11):2598-2608
pubmed: 28835386
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
J Clin Oncol. 2018 Feb 20;36(6):536-542
pubmed: 29320312
Nature. 2018 Feb 8;554(7691):189-194
pubmed: 29420467
Cancer Med. 2018 Mar;7(3):746-756
pubmed: 29436178